Clinical Trials

1,000 enrolled

Breast Neoplasms

NCT06324357 2026-04-15

Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread

Phase 1/2 Recruiting

768 enrolled

BreastGastrointestinal

Adenocarcinoma Of Esophagus, Breast Neoplasms, Colorectal Neoplasms

NCT04686305 2026-04-13

DL03

Phase 1 Recruiting

304 enrolled

Carcinoma, Non-Small-Cell Lung

NCT04482309 2026-04-09

DPT02

477 enrolled 2 FDA

Pancreatic Neoplasms, Colorectal Neoplasms

NCT06764875 2026-04-09

A Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer

840 enrolled

HER2-positive Gastric Cancer

NCT05950945 2026-04-08

Trastuzumab Deruxtecan (T-DXd) in Patients Who Have Hormone Receptor-negative and Hormone Receptor-positive HER2-low or HER2 IHC 0 Metastatic Breast Cancer

250 enrolled

Breast Neoplasms

NCT06989112 2026-04-08

DE-01

600 enrolled

Gynecologic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Uterine Neoplasms, Endometrial Neoplasms

NCT05048797 2026-04-03

A Study to Investigate the Efficacy and Safety of Trastuzumab Deruxtecan as the First Treatment Option for Unresectable, Locally Advanced/Metastatic Non-Small Cell Lung Cancer With HER2 Mutations

454 enrolled

Phase 2 Not yet recruiting

Carcinoma, Non-Small-Cell Lung

NCT07497386 2026-03-27

A Trial of Trastuzumab Rezetecan in Unresectable Locally Recurrent/Metastatic Breast Cancer

150 enrolled

Unresectable Locally Recurrent Breast Cancer

NCT04539938 2026-03-23

HER2CLIMB-04

70 enrolled 23 charts

Breast Neoplasms

NCT04639219 2026-03-23

DPT01

102 enrolled 18 charts

Tumor-Agnostic

Neoplasm Metastasis

NCT07015697 2026-03-20

A Study of Subcutaneous Trastuzumab Deruxtecan in Participants With Metastatic Solid Tumors

Phase 1 Recruiting

76 enrolled

Recurrence

NCT03424005 2026-03-16

Morpheus-panBC

Phase 1/2 Recruiting

792 enrolled

Breast Neoplasms

NCT06731478 2026-03-16

Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer

726 enrolled

BreastCNSGastrointestinalGenitourinaryGynecologic

Stomach Neoplasms

NCT05417594 2026-03-12

CERTIS1

Phase 1/2 Recruiting

695 enrolled

Astrocytoma, Breast Neoplasms, Fallopian Tube Neoplasms, Glioma, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms

NCT07069712 2026-03-10

A Study of Novel Agents or Combinations as Perioperative Treatment in Participants With Locally Advanced Resectable Gastroesophageal Adenocarcinoma

100 enrolled

Stomach Neoplasms

NCT06819007 2026-03-05

DO-01

582 enrolled

Gynecologic

Carcinoma, Ovarian Epithelial, Ovarian Neoplasms

NCT04494425 2026-03-04

DB-06

866 enrolled 25 charts 3 FDA

Breast Neoplasms

NCT03523585 2026-02-27

DS-8201a in Pre-treated HER2 Breast Cancer That Cannot be Surgically Removed or Has Spread [DESTINY-Breast02]

Phase 3 Completed

608 enrolled 17 charts

Breast Neoplasms

NCT04379596 2026-02-23

DG-03

450 enrolled

Adenocarcinoma, Carcinoma, Esophageal Neoplasms, Stomach Neoplasms

NCT05113251 2026-02-23

Trastuzumab Deruxtecan (T-DXd) Alone or in Sequence With THP, Versus Standard Treatment (ddAC-THP), in HER2-positive Early Breast Cancer

927 enrolled

Breast Neoplasms

NCT04784715 2026-02-20

Trastuzumab Deruxtecan (T-DXd) With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer (DESTINY-Breast09)

1,157 enrolled 3 FDA

Breast Diseases, Breast Neoplasms, Neoplasm Metastasis

NCT04739761 2026-02-11

DESTINY-B12

Phase 1/2 Active not recruiting

506 enrolled 27 charts

BreastCNS

Brain Neoplasms, Breast Neoplasms

NCT06244485 2026-02-04

A Study of Valemetostat Tosylate in Combination With DXd ADCs in Subjects With Solid Tumors

Phase 1 Recruiting

210 enrolled

Other solid neoplasm

Advanced Solid Tumor

NCT06771622 2026-02-04

Safety and Efficacy of HCB101 in Combination With Multiple Agents in Patients With Advanced Solid Tumors

500 enrolled

Solid Cancer

NCT07022483 2026-02-04

Study of Trastuzumab Deruxtecan Versus Standard of Care Chemotherapy for HER2-Expressing (IHC 3+/2+) Endometrial Cancer

Phase 1/2 Active not recruiting

710 enrolled

Gynecologic

Neoplasms, Endometrial Neoplasms

NCT03742102 2026-02-02

BEGONIA

243 enrolled 13 charts

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT04744831 2026-01-14

DESTINY-CRC02

122 enrolled 21 charts 2 FDA

Colorectal Neoplasms

NCT04704934 2026-01-12

Trastuzumab Deruxtecan for Subjects With HER2-Positive Gastric Cancer or Gastro-Esophageal Junction Adenocarcinoma After Progression on or After a Trastuzumab-Containing Regimen (DESTINY-Gastric04)

490 enrolled

Adenocarcinoma, Stomach Neoplasms

NCT06899126 2026-01-08

DESTINY-Lung06

686 enrolled

Phase 1 Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT04556773 2025-12-17

DB-08

138 enrolled

Phase 1/2 Active not recruiting

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT04538742 2025-12-08

DB-07

245 enrolled

BreastCNS

Brain Neoplasms, Breast Neoplasms

NCT06429761 2025-11-24

STRIDE

Phase 4 Recruiting

100 enrolled

Breast Neoplasms

NCT04644237 2025-11-21

DESTINY-LUNG02

152 enrolled 22 charts 1 FDA

Phase 1 Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT04042701 2025-11-18

DS8201a and Pembrolizumab in Participants With Locally Advanced/Metastatic Breast or Non-Small Cell Lung Cancer

115 enrolled

BreastThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung

NCT03334617 2025-10-27

HUDSON

528 enrolled 16 charts

Carcinoma, Non-Small-Cell Lung

NCT06271837 2025-10-22

A Study of T-DXd as Monotherapy or in Combination With Anti-cancer Agents in Patients With Selected HER2-expressing Tumors

175 enrolled

Breast Neoplasms

NCT03529110 2025-10-21

DS-8201a Versus T-DM1 for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive, Unresectable and/or Metastatic Breast Cancer Previously Treated With Trastuzumab and Taxane [DESTINY-Breast03]

524 enrolled 11 charts 2 FDA

Breast Neoplasms

NCT06174987 2025-10-15

A Study to Provide Continued Access to and Assess Long-Term Safety of the Study Drug(s)

50 enrolled

Tumor-Agnostic

Neoplasm Metastasis

NCT03734029 2025-10-06

Trastuzumab Deruxtecan (DS-8201a) Versus Investigator's Choice for HER2-low Breast Cancer That Has Spread or Cannot be Surgically Removed [DESTINY-Breast04]

557 enrolled 22 charts 2 FDA

Phase 1/2 Not yet recruiting

Breast Neoplasms, Neoplasm Metastasis

NCT07157956 2025-09-05

CVL006-T1002

318 enrolled

Other solid neoplasm

Advanced Solid Tumor

NCT05246514 2025-08-28

DL-05

72 enrolled 16 charts

253 enrolled 21 charts 2 FDA

HER2-mutant Non-Small Cell Lung Cancer

NCT03248492 2025-06-26

DESTINY-Breast01

Phase 2 Terminated

Breast Neoplasms, Neoplasm Metastasis

NCT06832202 2025-06-15

A Phase II Study of HLX22 in Combination With Trastuzumab Deruxtecan in HER2-low, Hormone Receptor Positive Locally Advanced or Metastatic Breast Cancer Patients

50 enrolled

181 enrolled 17 charts 2 FDA

HER2-low Hormone Receptor Positive Breast Cancer

NCT03505710 2025-05-30

DESTINY-Lung01

Phase 2 Terminated

Phase 1 Active not recruiting

Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis

NCT05765851 2025-05-11

A Study of DS-1103a Combination Therapy in Participants With Advanced Solid Tumors

78 enrolled

Breast Neoplasms

NCT04622319 2025-05-09

DESTINY-Breast05

1,600 enrolled

HER2-Positive Primary Breast Cancer

NCT04014075 2025-04-03

DS-8201a in HER2-positive Gastric Cancer That Cannot Be Surgically Removed or Has Spread (DESTINY-Gastric02)